Oxford Nanopore Technologies PLC
LSE:ONT

Watchlist Manager
Oxford Nanopore Technologies PLC Logo
Oxford Nanopore Technologies PLC
LSE:ONT
Watchlist
Price: 142.5 GBX 2.59% Market Closed
Market Cap: 1.4B GBX

Oxford Nanopore Technologies PLC
Investor Relations

Oxford Nanopore Technologies PLC stands as a pioneering force in the field of genomics, transforming the landscape of DNA and RNA sequencing. Founded as a spin-off from the University of Oxford, the company gained recognition with its distinctive nanopore sequencing technology, which radically differs from traditional sequencing methods. Traditional sequencing often involves a process that can be expensive, time-consuming, and complex. However, Oxford Nanopore's approach uses tiny, porous apertures coupled with electrical signals to read genetic codes directly. This technology allows for the sequencing of long DNA strands in real-time, providing not only speed and efficiency but also the versatility to handle a wide range of samples, from environmental to clinical applications. By making sequencing more accessible and portable through their critically acclaimed MinION device, the company has managed to capture significant interest and investment from researchers across diverse scientific fields.

The business model of Oxford Nanopore Technologies is built upon a strategic blend of product sales, including their sequencing devices and associated consumables, alongside providing commercial sequencing services. Their revenue streams are anchored by the MinION, GridION, and PromethION devices, each catering to varied throughput needs and scales of operation. Sales of these devices are complemented by a continuous income from consumable sales, essential for each sequencing run, which helps to embed their technology deeply within the workflows of their users. Additionally, the company's expansion into data analysis services further diversifies their income, utilizing their specialized expertise to assist customers in interpreting and utilizing complex genomic data. This multifaceted approach not only solidifies their position in the genomics market but also ensures multiple pathways for generating sustained revenue growth.

Show more
Loading
ONT
FTSE All Share Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2025
Call Date
Sep 2, 2025
AI Summary
Q2 2025

Revenue Beat: Oxford Nanopore delivered first-half revenue of £105.6 million, up 28% at constant currency and ahead of expectations.

Gross Margin: Gross margin was 58.2%, just below the 59% target due to a one-off inventory charge; excluding this, margin would have been 61%.

Improved Profitability: Adjusted EBITDA loss improved by 22% year-on-year, reflecting better gross profits and disciplined cost control.

Strong Guidance Reaffirmed: Management reaffirmed full-year guidance for 20–23% constant currency revenue growth and a 59% gross margin.

Pricing Model Success: The shift to a CapEx-first pricing model boosted gross margin and improved cash flow, with further benefits expected as more customers adopt the model.

Applied Markets Growth: Applied markets now make up 32% of revenue, with clinical revenue up 53% and biopharma up 19%.

Cash Position: Net cash stands at £337 million, with improved cash burn and a clear path to cash flow breakeven by 2028.

CEO Transition: CEO Gordon Sanghera will step down at the end of next year after over two decades leading the company.

Key Financials
Revenue
£105.6 million
Gross Margin
58.2%
Adjusted EBITDA Loss
£48.3 million
Net Cash
£337 million
Consumables Revenue
74% of total revenues
Earnings Call Recording
Other Earnings Calls
2025

Management

Dr. James Spike Willcocks
Chief Strategy Officer
No Bio Available
Prof. Hagan Bayley Ph.D.
Co-Founder & Member of Technical Advisory Board
No Bio Available
Mr. Nicholas Patrick Keher
CFO & Director
No Bio Available
Mr. Lakmal Jayasinghe
Chief Scientific Officer
No Bio Available
Mr. John Schoellerman
Senior Vice President of Corporate & Business Development
No Bio Available
Ms. Rosemary Sinclair Dokos M.B.A.
Chief Product & Marketing Officer
No Bio Available
Mr. Richard Compton
Senior Vice President of Sales & Commercial Operations
No Bio Available
Ms. Sarah Lapworth
Senior Vice President of Global Human Resources
No Bio Available
Ms. Zoe McDougall
Global Head & Senior VP of Corporate Affairs
No Bio Available
Kathleen Barnes
Senior Vice President of Population Health & Precision Medicine
No Bio Available

Contacts

Address
OXFORD
Oxford Science Park, Gosling Building, Edmund Halley Road
Contacts
+448450347900.0
www.nanoporetech.com